Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Takes Stake in CardioDx; Forms MDx Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare has invested $5 million in molecular diagnostics firm CardioDx as part of a Series D round of financing for the startup.

GE Healthcare also said that it has formed an alliance with the Palo Alto, Calif.-based firm to co-develop diagnostic technologies for the care and management of patients with cardiovascular disease.

CardioDx is developing a gene expression-based test, called Corus CAD, that is aimed at determining the likelihood that a patient has obstructive coronary artery disease. Such a test would enable physicians to determine a patient's status non-invasively, rather than through a combination of invasive and non-invasive methods.

The $5 million equity investment was made through the GE Healthymagination Fund, a $250 million fund which seeks to invest in firms developing technologies with the potential of reducing cost, increasing access, and improving quality in healthcare, said GE. The firms did not disclose the percentage of CardioDx equity that GE now owns.

"The alliance with CardioDx gives us access to new and exciting technologies in high-value diagnostics, which will complement and strengthen our existing offerings," Pascale Witz, president and CEO of GE Healthcare's Medical Diagnostics business, said in a statement. "CardioDx is an excellent strategic fit with GE Healthcare, given our common focus on cardiovascular disease."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.